Our findings demonstrate that dysregulation of key miRNA biogenesis genes, particularly DROSHA, DICER1, DGCR8, and TARBP2, is associated with hematopoietic disruption in newly diagnosed MDS and AML patients. This evidence concerns the gene TARBP2 and myelodysplastic syndrome.